As described above, host immune cells such as TANs and TAMs contribute to some of the proposed mechanisms of anti-VEGF therapy resistance [47,48,52,145]
As described above, host immune cells such as TANs and TAMs contribute to some of the proposed mechanisms of anti-VEGF therapy resistance [47,48,52,145]. the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients. gene [6] (Physique 1). Among these, VEGF121 and VEGF165 are the two major isoforms.…